Table 4.
Clinical features of essential thrombocythemia patients experiencing and not experiencing thrombotic events
| Variable | With TE (n = 42) | Without TE (n = 97) | p value |
|---|---|---|---|
| Age, yr | 67.6 ± 12.8 | 57.2 ± 15.2 | 0.000 |
| Male sex | 28 (66.7) | 42 (43.3) | 0.011 |
| Laboratory findings | |||
| WBC, × 109/L | 11.5 ± 4.8 | 10.9 ± 4.4 | 0.508 |
| Monocytes, × 109/L | 0.7 ± 0.5 | 0.6 ± 0.3 | 0.061 |
| Hemoglobin, g/dL | 13.8 ± 1.8 | 12.5 ± 2.3 | 0.437 |
| Platelets, × 109/L | 979.0 ± 387.9 | 936.6 ± 388.0 | 0.555 |
| LDH, × UNL | 1.1 ± 0.3 | 1.2 ± 0.5 | 0.667 |
| Driver gene mutation | |||
| JAK2V617F | 26/32 (81.3) | 54/85 (63.5) | 0.045 |
| CALR | 2/32 (6.3) | 12/85 (14.1) | 0.058 |
| IPSET | 0.000 | ||
| Low | 1 (2.4) | 42 (43.3) | |
| Intermediate | 4 (9.5) | 38 (39.2) | |
| High | 54 (88.1) | 17 (17.5) | |
| R-IPSET-T | 0.000 | ||
| Very low | 1 (2.4) | 21 (21.6) | |
| Low | 0 (0.0) | 25 (25.8) | |
| Intermediate | 1 (2.4) | 7 (7.2) | |
| High | 36 (85.7) | 33 (34.0) | |
| Comorbidity | |||
| Hypertension | 24 (57.1) | 26 (26.8) | 0.001 |
| Diabetes mellitus | 5 (11.9) | 14 (14.4) | 0.690 |
| Chronic kidney disease | 15 (35.7) | 6 (6.2) | 0.000 |
| Smoking | 14 (33.3) | 10 (10.3) | 0.001 |
| Hemorrhagic event | 2 (4.8) | 7 (7.2) | 0.723 |
| Follow-up duration, yr | 5.6 ± 5.8 | 6.2 ± 5.9 | 0.570 |
Values are presented as mean ± SD or number (%).
TE, thrombotic event; WBC, white blood cell; LDH, lactate dehydrogenase; UNL, upper normal limit; JAK2, Janus kinase 2; CALR, calreticulin; IPSET, International Prognostic Score in Essential Thrombocythemia; R-IPSET-T, revised IPSET-thrombosis score.